查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2089695

藥品安全監測市場規模、佔有率和趨勢分析報告：按產品生命週期、服務供應商、類型、治療領域、流程、最終用途、地區和細分市場進行預測（2026-2033 年）

Pharmacovigilance Market Size, Share & Trends Analysis Report By Product Life Cycle, By Service Provider, By Type, By Therapeutic Area, By Process Flow, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 190 Pages | 商品交期: 2-10個工作天內

價格

藥物安全監測市場概述

全球藥品安全監測市場預計到 2025 年將擴大到 135 億美元，2026 年至 2033 年的複合年成長率為 5.6%。

到 2025 年，北美主導市場，佔據最大佔有率，達到 31.7%。藥物濫用導致的不利事件(ADR) 發生率上升以及需要使用多種藥物的疾病的普遍存在是成長要素。

此外，新藥生產的擴張以及政府對藥品安全嚴格的法規結構顯著推動了市場成長。例如，美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）已製定了涵蓋臨床試驗各個階段的監管指南。此外，不良反應資料庫和資訊系統的發展使得資訊報告更加準確，研究人員現在可以更有效地利用這些資訊進行前瞻性臨床研究，從而加速整體市場成長。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 波特五力分析
  • PESTEL 分析
  • 價值鏈分析
  • 生命週期、服務提供與需求之間的關係。
  • 法律規範
  • 定價模式
  • 技術歷史沿革概述
  • 市場趨勢
  • 通貨膨脹的影響
  • 案例研究

第4章：藥品安全監測市場：依產品生命週期分類的估算與趨勢分析

  • 按產品生命週期分類的市佔率波動分析（2025 年和 2033 年）
  • 市場規模、預測和趨勢分析（按產品生命週期分類，2021-2033 年 / 十億美元）
    • 臨床前階段
    • 第一階段
    • 第二階段
    • 第三階段
    • 第四階段

第5章：藥品安全監測市場：服務供應商的估算與趨勢分析

  • 服務供應商儀錶板
  • 2025 年及 2033 年服務供應商市場佔有率及波動分析
  • 市場規模、預測和趨勢分析（按服務供應商，2021-2033 年 / 十億美元）
  • 內部回應
  • 外包

第6章：藥品安全監測市場：按類型分類的估算與趨勢分析

  • 按類型分類的市場佔有率和波動分析（2025 年和 2033 年）
  • 市場規模、預測和趨勢分析（按類型，2021-2033 年 / 十億美元）
  • 自願報告
  • 加強不良事件報告
  • 有針對性的自願報告
  • 隊列事件監測（CEM）
  • EHR Mining

第7章：藥物安全監測市場：依流程分類的估算與趨勢分析

  • 按製程流程分類的市佔率波動分析（2025 年和 2033 年）
  • 市場規模、預測和趨勢分析（按工藝流程分類，2021-2033 年 / 十億美元）
  • 案例資料管理
  • 醫學審查和報告
  • 訊號檢測
  • 風險管理系統

第8章：藥物安全監測市場：按治療領域分類的估算與趨勢分析

  • 按治療區域分類的市場佔有率和波動分析（2025 年和 2033 年）
  • 市場規模、預測和趨勢分析（按治療領域分類，2021-2033 年 / 十億日圓）
  • 腫瘤學
  • 神經病學
  • 循環系統
  • 呼吸系統
  • 其他

第9章：藥品安全監測市場：區域估算與趨勢分析

  • 區域市場概覽
  • 區域市場：要點
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第10章：藥品安全監測市場：競爭分析

  • 參與企業的分類
  • 公司市場分析
  • 企業市場占有率分析，2025 年
  • Competitive Factors and Strategies
    • 策略合作夥伴關係增加和新產品發布
    • 政府的策略性措施（包括合作）
    • 競爭對手擴大了藥物安全意識宣傳計畫。
    • 競爭對手加強了合作，並擴大了業務外包規模。
    • 產業重組趨勢

第11章 競爭格局

  • 公司簡介
    • Accenture
    • IQVIA Inc.
    • Cognizant
    • Clinquest Group BV（Linical Americas）
    • IBM
    • Laboratory Corporation of America Holdings
    • ArisGlobal
    • Capgemini
    • ITClinical
    • ICON plc.
    • TAKE Solutions Limited
    • Parexel International（MA）Corporation
    • Wipro
    • United BioSource LLC
    • BioClinica Inc.（Clario）
    • ClinChoice（formerly FMD K&L）

第12章：制勝策略

  • 主要勝利條件/計分標準
    • 按類別
    • 供應商選擇的關鍵因素

第13章：轉換成本分析

Product Code: 978-1-68038-327-0

Pharmacovigilance Market Summary

The global pharmacovigilance market size was valued at USD 8.6 billion in 2025 and is projected to grow from USD 9.2 billion in 2026 to USD 13.5 billion by 2033, growing at a CAGR of 5.6% from 2026 to 2033. America dominated the market in 2025 and held the largest share of 31.7%. The rising incidence of Adverse Drug Reactions (ADRs) owing to drug abuse and the prevalence of diseases that require a combination of drugs are the major growth drivers for the market.

In addition, an upward shift in the production of novel drugs and the presence of stringent government regulatory frameworks for drug safety are significantly boosting the market growth. For instance, the U.S. FDA and the European Medicines Agency (EMA) issue regulatory guidelines for all phases of clinical trials. Moreover, advancements in the development of ADR databases and information systems have enabled accurate reporting of information, which can be further utilized by research professionals for prospective clinical studies, thereby fueling overall growth.

Global Pharmacovigilance Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharmacovigilance market report based on service provider, product life cycle, type, process flow, therapeutic area, end use, and region:

  • Product Life Cycle Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Service Provider Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • In-house
  • Contract Outsourcing
  • Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining
  • End Use Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Pharmaceuticals
  • Biotechnology Companies
  • Medical Device Manufacturers
  • Others
  • Therapeutic Area Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Oncology
  • Neurology
  • Cardiology
  • Respiratory Systems
  • Others
  • Process Flow Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Case Data Management
    • Case Logging
    • Case Data Analysis
  • Medical Reviewing & Reporting
  • Signal Detection
    • Adverse Event Logging
    • Adverse Event Analysis
    • Adverse Event Review & Reporting
  • Risk Management System
    • Risk Evaluation System
    • Risk Mitigation System
  • Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
    • Russia
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product Life Cycle
    • 1.2.2. Service Provider
    • 1.2.3. Type
    • 1.2.4. Process Flow
    • 1.2.5. Therapeutic area
    • 1.2.6. End use
    • 1.2.7. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
      • 1.5.4.1. Details of Primary Research
      • 1.5.4.2. Data for primary interviews in North America
      • 1.5.4.3. Data for Primary Interviews in Europe
      • 1.5.4.4. Data for Primary Interviews in APAC
      • 1.5.4.5. Data for Primary Interviews in Latin America
      • 1.5.4.6. Data for Primary Interviews in MEA
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Report Objectives
    • 1.10.1. Objective-1
    • 1.10.2. Objective-2

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
    • 2.2.1. Segment Snapshot (Product Life Cycle & Type)
    • 2.2.2. Segment Snapshot (Process Flow & Therapeutic Area)
    • 2.2.3. Segment Snapshot (End Use)
    • 2.2.4. Competitive Landscape Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing drug consumption and drug development rates
      • 3.2.1.2. Increasing incidence of ADR and drug toxicity
      • 3.2.1.3. Increasing trend of outsourcing pharmacovigilance services
      • 3.2.1.4. Increasing externalization of clinical trial studies by large
      • 3.2.1.5. Increasing Regulatory Burden on Manufacturers
      • 3.2.1.6. Introduction of technologically advanced software services
        • 3.2.1.6.1.Key focus areas for the pharmaceutical/healthcare companies
        • 3.2.1.6.2.Adoption of technological advancements in the life sciences industry
        • 3.2.1.6.3.Published Survey insights - related to the adoption of pharmacovigilance automation
      • 3.2.1.7. Rising investment on R&D by healthcare companies
      • 3.2.1.8. Partnerships and collaborations between market players
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Shortage of skilled labor
      • 3.2.2.2. Expensive technology for small- and mid-sized players
      • 3.2.2.3. Lack of recognition
      • 3.2.2.4. Scarcity of integration standards
    • 3.2.3. Industry Opportunity Analysis
    • 3.2.4. Industry Challenge Analysis
  • 3.3. Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
  • 3.4. PESTLE Analysis
  • 3.5. Value Chain Analysis
    • 3.5.1. Preclinical
    • 3.5.2. Clinical
    • 3.5.3. PMA
  • 3.6. Mapping of Life Cycle Against Service Offering and Their Demand
  • 3.7. Regulatory Framework
    • 3.7.1. List of regulatory bodies by Country
  • 3.8. Pricing Models
    • 3.8.1. Drug safety budget allocation by activities
    • 3.8.2. By development phase
    • 3.8.3. By therapeutic area
    • 3.8.4. Pricing level
      • 3.8.4.1. Project management
      • 3.8.4.2. Case processing
      • 3.8.4.3. ADR Reporting
      • 3.8.4.4. Medical writing
      • 3.8.4.5. Drug safety management
  • 3.9. Technology Timeline Overview
    • 3.9.1. Changing Technology & Adoption
    • 3.9.2. Current Technology Landscape of PV
    • 3.9.3. IQVIA's AI-Driven Transformation in Pharmacovigilance
    • 3.9.4. Tech Mahindra's AI-Driven Pharmacovigilance Solution in
    • 3.9.5. The evolving PV workload with AI assistance
    • 3.9.6. Social Media
      • 3.9.6.1. Literature screening
      • 3.9.6.2. Automation and AI
      • 3.9.6.3. Big data analytics in PV
  • 3.10. Market Trend
    • 3.10.1. Scaling of resources
    • 3.10.2. Automation in Pharmacovigilance
  • 3.11. Impact of Inflation
  • 3.12. Case Studies
    • 3.12.1. Potential Customers
    • 3.12.2. Notable Use Cases
    • 3.12.3. Case Study 1
      • 3.12.3.1. Part 1
      • 3.12.3.2. Part 2
    • 3.12.4. Case Study 2
    • 3.12.5. Case Study 3
    • 3.12.6. Case Study 4

Chapter 4. Pharmacovigilance Market: Product Life Cycle Estimates & Trend Analysis

  • 4.1. Product Life Cycle Segment Dashboard
  • 4.2. Product Life Cycle Market Share Movement Analysis, 2025 & 2033
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product Life Cycle, 2021 to 2033 (USD Million/Billion)
    • 4.3.1. Preclinical
      • 4.3.1.1. Preclinical market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.3.2. Phase I
      • 4.3.2.1. Phase I market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.3.3. Phase II
      • 4.3.3.1. Phase II market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.3.4. Phase III
      • 4.3.4.1. Phase III market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.3.5. Phase IV
      • 4.3.5.1. Phase IV market estimates and forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 5. Pharmacovigilance Market Service Provider Estimates & Trend Analysis

  • 5.1. Service Provider Dashboard
  • 5.2. Service Provider Market Share Movement Analysis, 2025 & 2033
  • 5.3. Market Size & Forecasts and Trend Analysis, by Service Provider, 2021 to 2033 (USD Million/Billion)
  • 5.4. In House
    • 5.4.1. In-house market, 2021 - 2033 (USD Million/Billion)
  • 5.5. Contract Outsourcing
    • 5.5.1. Contract Outsourcing market, 2021 - 2033 (USD Million/Billion)

Chapter 6. Pharmacovigilance Market: Type Estimates & Trend Analysis

  • 6.1. Type Segment Dashboard
  • 6.2. Type Market Share Movement Analysis, 2025 & 2033
  • 6.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million/Billion)
  • 6.4. Spontaneous Reporting
    • 6.4.1. Spontaneous Reporting market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.5. Intensified ADR Reporting
    • 6.5.1. Intensified ADR Reporting market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.6. Targeted Spontaneous Reporting
    • 6.6.1. Targeted spontaneous reporting market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.7. Cohort Event Monitoring (CEM)
    • 6.7.1. CEM market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.8. EHR Mining
    • 6.8.1. EHR Mining market estimates and forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 7. Pharmacovigilance Market: Process Flow Estimates & Trend Analysis

  • 7.1. Process Flow Segment Dashboard
  • 7.2. Process Flow Market Share Movement Analysis, 2025 & 2033
  • 7.3. Market Size & Forecasts and Trend Analysis, by Process Flow, 2021 to 2033 (USD Million/Billion)
  • 7.4. Case data management
    • 7.4.1. Case data management market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
      • 7.4.1.1. Case logging
        • 7.4.1.1.1.Case logging market, 2021 - 2033 (USD Million/Billion)
      • 7.4.1.2. Case data analysis
        • 7.4.1.2.1.Case data analysis market, 2021 - 2033 (USD Million/Billion)
  • 7.5. Medical reviewing and reporting
      • 7.5.1.1. Medical reviewing and reporting market, 2021 - 2033 (USD Million/Billion)
  • 7.6. Signal detection
    • 7.6.1. Signal detection market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
      • 7.6.1.1. Adverse Event Logging
        • 7.6.1.1.1.Adverse event logging market, 2021 - 2033 (USD Million/Billion)
      • 7.6.1.2. Adverse Event Analysis
        • 7.6.1.2.1.Adverse Event Analysis market, 2021 - 2033 (USD Million/Billion)
      • 7.6.1.3. Adverse Event Review & Reporting
        • 7.6.1.3.1.Adverse Event Review & Reporting market, 2021 - 2033 (USD Million/Billion)
  • 7.7. Risk Management System
    • 7.7.1. Risk Management System market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
      • 7.7.1.1. Risk Evaluation System
        • 7.7.1.1.1.Risk Evaluation market, 2021 - 2033 (USD Million/Billion)
      • 7.7.1.2. Risk Mitigation System
        • 7.7.1.2.1.Risk Mitigation market, 2021 - 2033 (USD Million/Billion)

Chapter 8. Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis

  • 8.1. Therapeutic Area Segment Dashboard
  • 8.2. Therapeutic Area Market Share Movement Analysis, 2025 & 2033
  • 8.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million/Billion)
  • 8.4. Oncology
    • 8.4.1. Oncology market, 2021 - 2033 (USD Million/Billion)
  • 8.5. Neurology
    • 8.5.1. Neurology market, 2021 - 2033 (USD Million/Billion)
  • 8.6. Cardiology
    • 8.6.1. Cardiology market, 2021 - 2033 (USD Million/Billion)
  • 8.7. Respiratory Systems
    • 8.7.1. Respiratory Systems market, 2021 - 2033 (USD Million/Billion)
  • 8.8. Others
    • 8.8.1. Other market, 2021 - 2033 (USD Million/Billion)

Chapter 9. Pharmacovigilance Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Dashboard
  • 9.2. Regional Market: Key Takeaways
  • 9.3. North America
    • 9.3.1. North America Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.3.2. U.S.
      • 9.3.2.1. Key country dynamic
      • 9.3.2.2. Regulatory framework
      • 9.3.2.3. Competitive insights
      • 9.3.2.4. U.S. Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.3.3. Canada
      • 9.3.3.1. Key country dynamic
      • 9.3.3.2. Regulatory framework
      • 9.3.3.3. Competitive insights
      • 9.3.3.4. Canada Pharmacovigilance market estimates and forecasts, 2021 - 2033
    • 9.3.4. Mexico
      • 9.3.4.1. Key country dynamic
      • 9.3.4.2. Regulatory framework
      • 9.3.4.3. Competitive insights
      • 9.3.4.4. Mexico Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4. Europe
    • 9.4.1. Europe Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.4.2. Germany
      • 9.4.2.1. Key country dynamic
      • 9.4.2.2. Regulatory framework
      • 9.4.2.3. Competitive insights
      • 9.4.2.4. Germany Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.4.3. UK
      • 9.4.3.1. Key country dynamic
      • 9.4.3.2. Regulatory framework
      • 9.4.3.3. Competitive insights
      • 9.4.3.4. UK Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.4.4. France
      • 9.4.4.1. Key country dynamic
      • 9.4.4.2. Regulatory framework
      • 9.4.4.3. Competitive insights
      • 9.4.4.4. France Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.4.5. Italy
      • 9.4.5.1. Key country dynamic
      • 9.4.5.2. Regulatory framework
      • 9.4.5.3. Competitive insights
      • 9.4.5.4. Italy Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.4.6. Spain
      • 9.4.6.1. Key country dynamic
      • 9.4.6.2. Regulatory framework
      • 9.4.6.3. Competitive insights
      • 9.4.6.4. Spain Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.4.7. Russia
      • 9.4.7.1. Key country dynamic
      • 9.4.7.2. Regulatory framework
      • 9.4.7.3. Competitive insights
      • 9.4.7.4. Russia Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.4.8. Denmark
      • 9.4.8.1. Key country dynamic
      • 9.4.8.2. Regulatory framework
      • 9.4.8.3. Competitive insights
      • 9.4.8.4. Denmark Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.4.9. Sweden
      • 9.4.9.1. Key country dynamic
      • 9.4.9.2. Regulatory framework
      • 9.4.9.3. Competitive insights
      • 9.4.9.4. Sweden Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.4.10. Norway
      • 9.4.10.1. Key country dynamic
      • 9.4.10.2. Regulatory framework
      • 9.4.10.3. Competitive insights
      • 9.4.10.4. Norway Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.5. Asia Pacific
    • 9.5.1. Asia Pacific Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.5.2. Japan
      • 9.5.2.1. Key country dynamic
      • 9.5.2.2. Regulatory framework
      • 9.5.2.3. Competitive insights
      • 9.5.2.4. Japan Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.5.3. China
      • 9.5.3.1. Key country dynamic
      • 9.5.3.2. Regulatory framework
      • 9.5.3.3. Competitive insights
      • 9.5.3.4. China Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.5.4. India
      • 9.5.4.1. Key country dynamic
      • 9.5.4.2. Regulatory framework
      • 9.5.4.3. Competitive insights
      • 9.5.4.4. India Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.5.5. South Korea
      • 9.5.5.1. Key country dynamic
      • 9.5.5.2. Regulatory framework
      • 9.5.5.3. Competitive insights
      • 9.5.5.4. South Korea Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.5.6. Australia
      • 9.5.6.1. Key country dynamic
      • 9.5.6.2. Regulatory framework
      • 9.5.6.3. Competitive insights
      • 9.5.6.4. Australia Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.5.7. Thailand
      • 9.5.7.1. Key country dynamic
      • 9.5.7.2. Regulatory framework
      • 9.5.7.3. Competitive insights
      • 9.5.7.4. Thailand Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.6. Latin America
    • 9.6.1. Latin America Pharmacovigilance Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.6.2. Brazil
      • 9.6.2.1. Key country dynamic
      • 9.6.2.2. Regulatory framework
      • 9.6.2.3. Competitive insights
      • 9.6.2.4. Brazil Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
      • 9.6.2.5. (USD Million/Billion)
    • 9.6.3. Argentina
      • 9.6.3.1. Key country dynamic
      • 9.6.3.2. Regulatory framework
      • 9.6.3.3. Competitive insights
      • 9.6.3.4. Argentina Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.7. MEA
    • 9.7.1. MEA Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.7.2. South Africa
      • 9.7.2.1. Key country dynamic
      • 9.7.2.2. Regulatory framework
      • 9.7.2.3. Competitive insights
      • 9.7.2.4. South Africa Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.7.3. Saudi Arabia
      • 9.7.3.1. Key country dynamic
      • 9.7.3.2. Regulatory framework
      • 9.7.3.3. Competitive insights
      • 9.7.3.4. Saudi Arabia Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.7.4. UAE
      • 9.7.4.1. Key country dynamic
      • 9.7.4.2. Regulatory framework
      • 9.7.4.3. Competitive insights
      • 9.7.4.4. UAE Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.7.5. Kuwait
      • 9.7.5.1. Key country dynamic
      • 9.7.5.2. Regulatory framework
      • 9.7.5.3. Competitive insights
      • 9.7.5.4. Kuwait Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 10. Pharmacovigilance Market: Competitive Analysis

  • 10.1. Market Participant Categorization
  • 10.2. Company Market Position Analysis
  • 10.3. Company Market Share Analysis, 2025
  • 10.4. Competitive Factors and Strategies
    • 10.4.1. Increasing Strategic Collaborations and Product Launches
    • 10.4.2. Strategic Government initiatives, including collaborations
    • 10.4.3. Competitors increased PV Awareness programs
    • 10.4.4. Competitors increased collaboration and outsourcing of operations
    • 10.4.5. Consolidation Trends

Chapter 11. Competitive Landscape

  • 11.1. Company Profiles
    • 11.1.1. Accenture
      • 11.1.1.1. Overview
      • 11.1.1.2. Financial performance
      • 11.1.1.3. Product benchmarking
      • 11.1.1.4. Strategic initiatives
    • 11.1.2. IQVIA Inc.
      • 11.1.2.1. Overview
      • 11.1.2.2. Financial performance
      • 11.1.2.3. Product benchmarking
      • 11.1.2.4. Strategic initiatives
    • 11.1.3. Cognizant
      • 11.1.3.1. Overview
      • 11.1.3.2. Financial performance
      • 11.1.3.3. Product benchmarking
      • 11.1.3.4. Strategic initiatives
    • 11.1.4. Clinquest Group B.V. (Linical Americas)
      • 11.1.4.1. Overview
      • 11.1.4.2. Financial performance
      • 11.1.4.3. Product benchmarking
      • 11.1.4.4. Strategic initiatives
    • 11.1.5. IBM
      • 11.1.5.1. Overview
      • 11.1.5.2. Financial performance
      • 11.1.5.3. Product benchmarking
      • 11.1.5.4. Strategic initiatives
    • 11.1.6. Laboratory Corporation of America Holdings
      • 11.1.6.1. Overview
      • 11.1.6.2. Financial performance
      • 11.1.6.3. Product benchmarking
      • 11.1.6.4. Strategic initiatives
    • 11.1.7. ArisGlobal
      • 11.1.7.1. Overview
      • 11.1.7.2. Financial performance
      • 11.1.7.3. Product benchmarking
      • 11.1.7.4. Strategic initiatives
    • 11.1.8. Capgemini
      • 11.1.8.1. Overview
      • 11.1.8.2. Financial performance
      • 11.1.8.3. Product benchmarking
      • 11.1.8.4. Strategic initiatives
    • 11.1.9. ITClinical
      • 11.1.9.1. Overview
      • 11.1.9.2. Financial performance
      • 11.1.9.3. Products & Services benchmarking
      • 11.1.9.4. Strategic initiatives
    • 11.1.10. ICON plc.
      • 11.1.10.1. Overview
      • 11.1.10.2. Financial performance
      • 11.1.10.3. Product benchmarking
      • 11.1.10.4. Strategic initiatives
    • 11.1.11. TAKE Solutions Limited
      • 11.1.11.1. Overview
      • 11.1.11.2. Financial performance
      • 11.1.11.3. Product benchmarking
      • 11.1.11.4. Strategic initiatives
    • 11.1.12. Parexel International (MA) Corporation
      • 11.1.12.1. Overview
      • 11.1.12.2. Financial performance
      • 11.1.12.3. Product benchmarking
      • 11.1.12.4. Strategic initiatives
    • 11.1.13. Wipro
      • 11.1.13.1. Overview
      • 11.1.13.2. Financial performance
      • 11.1.13.3. Product benchmarking
      • 11.1.13.4. Strategic initiatives
    • 11.1.14. United BioSource LLC
      • 11.1.14.1. Overview
      • 11.1.14.2. Financial performance
      • 11.1.14.3. Product benchmarking
      • 11.1.14.4. Strategic initiatives
    • 11.1.15. BioClinica Inc. (Clario)
      • 11.1.15.1. Overview
      • 11.1.15.2. Financial performance
      • 11.1.15.3. Product benchmarking
      • 11.1.15.4. Strategic initiatives
    • 11.1.16. ClinChoice (formerly FMD K&L)
      • 11.1.16.1. Overview
      • 11.1.16.2. Financial performance
      • 11.1.16.3. Product benchmarking
      • 11.1.16.4. Strategic initiatives

Chapter 12. Winning Strategies

  • 12.1. Key Winning / Scoring Criteria
    • 12.1.1. By Categories
      • 12.1.1.1. Pharmaceuticals
      • 12.1.1.2. Biotech companies
      • 12.1.1.3. Medical device companies
    • 12.1.2. Key Vendor Selection Factors
      • 12.1.2.1. By Category
      • 12.1.2.2. BY Company size
          • 12.1.2.2.1.1. Key Takeaways

Chapter 13. Switching Cost Analysis

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 North America Pharmacovigilance market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 4 North America Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 5 North America Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 6 North America Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 7 North America Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 8 North America Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 9 North America Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 10 U.S. Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 11 U.S. Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 12 U.S. Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 13 U.S. Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 14 U.S. Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 15 U.S. Pharmacovigilance market, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 16 Canada Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 17 Canada Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 18 Canada Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 19 Canada Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 20 Canada Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 21 Canada Pharmacovigilance market, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 22 Mexico Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 23 Mexico Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 24 Mexico Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 25 Mexico Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 26 Mexico Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 27 Mexico Pharmacovigilance market, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 28 Europe Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 29 Europe Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 30 Europe Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 31 Europe Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 32 Europe Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 33 Europe Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 34 UK Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 35 UK Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 36 UK Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 37 UK Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 38 UK Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 39 UK Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 40 Germany Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 41 Germany Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 42 Germany Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 43 Germany Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 44 Germany Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 45 Germany Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 46 France Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 47 France Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 48 France Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 49 France Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 50 France Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 51 France Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 52 Italy Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 53 Italy Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 54 Italy Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 55 Italy Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 56 Italy Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 57 Italy Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 58 Spain Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 59 Spain Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 60 Spain Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 61 Spain Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 62 Spain Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 63 Spain Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 64 Russia Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 65 Russia Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 66 Russia Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 67 Russia Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 68 Russia Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 69 Russia Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 70 Norway Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 71 Norway Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 72 Norway Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 73 Norway Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 74 Norway Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 75 Norway Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 76 Sweden Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 77 Sweden Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 78 Sweden Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 79 Sweden Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 80 Sweden Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 81 Sweden Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 82 Denmark Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 83 Denmark Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 84 Denmark Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 85 Denmark Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 86 Denmark Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 87 Denmark Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 88 Asia Pacific Pharmacovigilance market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 89 Asia Pacific Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 90 Asia Pacific Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 91 Asia Pacific Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 92 Asia Pacific Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 93 Asia Pacific Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 94 Asia Pacific Pharmacovigilance market, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 95 Japan Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 96 Japan Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 97 Japan Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 98 Japan Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 99 Japan Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 100 China Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 101 China Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 102 China Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 103 China Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 104 China Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 105 China Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 106 India Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 107 India Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 108 India Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 109 India Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 110 India Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 111 India Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 112 Australia Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 113 Australia Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 114 Australia Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 115 Australia Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 116 Australia Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 117 Australia Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 118 South Korea Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 119 South Korea Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 120 South Korea Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 121 South Korea Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 122 South Korea Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 123 South Korea Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 124 Thailand Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 125 Thailand Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 126 Thailand Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 127 Thailand Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 128 Thailand Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 129 Thailand Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 130 Latin America Pharmacovigilance market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 131 Latin America Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 132 Latin America Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 133 Latin America Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 134 Latin America Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 135 Latin America Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 136 Latin America Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 137 Brazil Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 138 Brazil Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 139 Brazil Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 140 Brazil Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 141 Brazil Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 142 Brazil Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 143 Argentina Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 144 Argentina Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 145 Argentina Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 146 Argentina Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 147 Argentina Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 148 Argentina Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 149 Middle East & Africa Pharmacovigilance market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 150 Middle East & Africa Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 151 Middle East & Africa Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 152 Middle East & Africa Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 153 Middle East & Africa Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 154 Middle East & Africa Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 155 Middle East & Africa Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 156 South Africa Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 157 South Africa Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 158 South Africa Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 159 South Africa Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 160 South Africa Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 161 South Africa Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 162 Saudi Arabia Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 163 Saudi Arabia Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 164 Saudi Arabia Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 165 Saudi Arabia Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 166 Saudi Arabia Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 167 Saudi Arabia Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 168 UAE Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 169 UAE Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 170 UAE Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 171 UAE Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 172 UAE Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 173 UAE Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)
  • Table 174 Kuwait Pharmacovigilance market, by product life cycle, 2021 - 2033 (USD Million/Billion)
  • Table 175 Kuwait Pharmacovigilance market, by service provider, 2021 - 2033 (USD Million/Billion)
  • Table 176 Kuwait Pharmacovigilance market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 177 Kuwait Pharmacovigilance market, by process flow, 2021 - 2033 (USD Million/Billion)
  • Table 178 Kuwait Pharmacovigilance market, therapeutic area, 2021 - 2033 (USD Million/Billion)
  • Table 179 Kuwait Pharmacovigilance market, end use, 2021 - 2033 (USD Million/Billion)

List of Figures

  • Fig. 1 Pharmacovigilance market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market formulation & validation
  • Fig. 6 Market research approaches
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD modelling for market share assessment
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Market snapshot
  • Fig. 11 Market segmentation (USD Million/Billion)
  • Fig. 12 Competitive landscape
  • Fig. 13 Parent market outlook (In USD Billion)
  • Fig. 14 Related/ancillary market outlook (In USD Billion)
  • Fig. 15 Pharmacovigilance market dynamics
  • Fig. 16 Pharmacovigilance market: Porter's five forces analysis
  • Fig. 17 Pharmacovigilance market: PESTLE analysis
  • Fig. 18 Pharmacovigilance market: product life cycle segment dashboard
  • Fig. 19 Pharmacovigilance market: product life cycle market share analysis, 2025 & 2033
  • Fig. 20 Preclinical market, 2021 - 2033 (USD Million/Billion)
  • Fig. 21 Phase I market, 2021 - 2033 (USD Million/Billion)
  • Fig. 22 Phase II market, 2021 - 2033 (USD Million/Billion)
  • Fig. 23 Phase III market, 2021 - 2033 (USD Million/Billion)
  • Fig. 24 Phase IV market, 2021 - 2033 (USD Million/Billion)
  • Fig. 25 Pharmacovigilance market: Service provider movement analysis
  • Fig. 26 Pharmacovigilance Service provider dashboard
  • Fig. 27 Pharmacovigilance market: product life cycle segment dashboard
  • Fig. 28 Pharmacovigilance market: product life cycle market share analysis, 2025 & 2033
  • Fig. 29 In-house market, 2021 - 2033 (USD Million/Billion)
  • Fig. 30 contract outsourcing market, 2021 - 2033 (USD Million/Billion)
  • Fig. 31 Pharmacovigilance market: Type movement analysis
  • Fig. 32 Pharmacovigilance type dashboard
  • Fig. 33 Pharmacovigilance market: product life cycle segment dashboard
  • Fig. 34 Pharmacovigilance market: product life cycle market share analysis, 2025 & 2033
  • Fig. 35 Spontaneous reporting market, 2021 - 2033 (USD Million/Billion)
  • Fig. 36 Intensified ADR reporting market, 2021 - 2033 (USD Million/Billion)
  • Fig. 37 Targeted spontaneous reporting market, 2021 - 2033 (USD Million/Billion)
  • Fig. 38 CEM market, 2021 - 2033 (USD Million/Billion)
  • Fig. 39 EHR mining market, 2021 - 2033 (USD Million/Billion)
  • Fig. 40 Pharmacovigilance market: process flow segment dashboard
  • Fig. 41 Pharmacovigilance market: process flow market share analysis, 2025 & 2033
  • Fig. 42 Case data management market, 2021 - 2033 (USD Million/Billion)
  • Fig. 43 Case logging market, 2021 - 2033 (USD Million/Billion)
  • Fig. 44 Case data analysis market, 2021 - 2033 (USD Million/Billion)
  • Fig. 45 Medical reviewing and reporting market, 2021 - 2033 (USD Million/Billion)
  • Fig. 46 Signal detection market, 2021 - 2033 (USD Million/Billion)
  • Fig. 47 Adverse event logging market, 2021 - 2033 (USD Million/Billion)
  • Fig. 48 Adverse event analysis market, 2021 - 2033 (USD Million/Billion)
  • Fig. 49 Adverse event review & reporting market, 2021 - 2033 (USD Million/Billion)
  • Fig. 50 Risk management system market, 2021 - 2033 (USD Million/Billion)
  • Fig. 51 Risk Evaluation System market, 2021 - 2033 (USD Million/Billion)
  • Fig. 52 Risk mitigation system market, 2021 - 2033 (USD Million/Billion)
  • Fig. 53 Pharmacovigilance market: therapeutic area segment dashboard
  • Fig. 54 Pharmacovigilance market: therapeutic area market share analysis, 2025 & 2033
  • Fig. 55 Oncology market, 2021 - 2033 (USD Million/Billion)
  • Fig. 56 Neurology market, 2021 - 2033 (USD Million/Billion)
  • Fig. 57 Cardiology market, 2021 - 2033 (USD Million/Billion)
  • Fig. 58 Respiratory systems market, 2021 - 2033 (USD Million/Billion)
  • Fig. 59 Others market, 2021 - 2033 (USD Million/Billion)
  • Fig. 60 Pharmacovigilance market: end use segment dashboard
  • Fig. 61 Pharmacovigilance market: end use market share analysis, 2025 & 2033
  • Fig. 62 Pharmaceuticals market, 2021 - 2033 (USD Million/Billion)
  • Fig. 63 Biotechnology companies' market, 2021 - 2033 (USD Million/Billion)
  • Fig. 64 Medical device manufacturers market, 2021 - 2033 (USD Million/Billion)
  • Fig. 65 Others market, 2021 - 2033 (USD Million/Billion)
  • Fig. 66 Pharmacovigilance market revenue, by region
  • Fig. 67 Regional marketplace: Key takeaways
  • Fig. 68 North America Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 69 Key country dynamics
  • Fig. 70 U.S. Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 71 Key country dynamics
  • Fig. 72 Canada Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 73 Key country dynamics
  • Fig. 74 Mexico Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 75 Key country dynamics
  • Fig. 76 Europe Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 77 Key country dynamics
  • Fig. 78 UK Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 79 Key country dynamics
  • Fig. 80 Germany Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 81 Key country dynamics
  • Fig. 82 France Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 83 Key country dynamics
  • Fig. 84 Italy Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 85 Key country dynamics
  • Fig. 86 Spain Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 87 Key country dynamics
  • Fig. 88 Norway Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 89 Key country dynamics
  • Fig. 90 Sweden Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 91 Key country dynamics
  • Fig. 92 Russia Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 93 Key country dynamics
  • Fig. 94 Denmark Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 95 Asia Pacific Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 96 Key country dynamics
  • Fig. 97 Japan Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 98 Key country dynamics
  • Fig. 99 China Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 100 Key country dynamics
  • Fig. 101 India Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 102 Key country dynamics
  • Fig. 103 Australia Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 104 Key country dynamics
  • Fig. 105 South Korea Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 106 Key country dynamics
  • Fig. 107 Thailand Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 108 Latin America Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 109 Key country dynamics
  • Fig. 110 Brazil Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 111 Key country dynamics
  • Fig. 112 Argentina Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 113 Key country dynamics
  • Fig. 114 MEA Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 115 Key country dynamics
  • Fig. 116 South Africa Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 117 Key country dynamics
  • Fig. 118 Saudi Arabia Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 119 Key country dynamics
  • Fig. 120 UAE Pharmacovigilance market, 2021 - 2033 (USD Million/Billion)
  • Fig. 121 Key country dynamics
  • Fig. 122 Kuwait healthcare information system market, 2021 - 2033 (USD Million/Billion)
  • Fig. 123 Key country dynamics
  • Fig. 124 Company categorization
  • Fig. 125 Company market position analysis
  • Fig. 126 Company market share analysis
  • Fig. 127 Strategic framework